Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Jun 23, 2019 11:39am
44 Views
Post# 29853698

RE:RE:RE:RE:Meir lost the vote 1.5 months ago!

RE:RE:RE:RE:Meir lost the vote 1.5 months ago!Well said Dasu, I do feel that by next spring if Goodman does not change his mode of operandi institutional investors will have had enogh and they will support a coup organized by someone else other than Meir. There will be plenty of of sound investors/activist as they will not continue to listen and tollarate the same old insane GUD non extistent financial plan.  As such it is worth waiting as good thing will come in the next 12 months either by GUD agresive actions "which I doubt as they are too busy else where" or from other activist GUD investors. There are many good CEO that would salivate to dedicate full time and resources to find good investment for GUD investors unlike the current do nothing MNGT. As well Mr. Goodman if he wants he is free to sell his shares at these price the same way Meir is now.  It is absurd for anyone to believe that in the past five Years there were no good multiple mid size biotech deal to buy or get involved into. It is well documented by the media that many good deals have been made by many other companies except no deals GUD investors. 
Why GUD got none of them it is no longer a mystery. The only thing that I know for sure  about MR Goodman is that he knows well that institutional investors respectfully has given him one more Year to change. Meir know this well and he will be making news at every step that GUD makes. Next year he only has to say to investors: Did I not tell you so? 
Bullboard Posts